Reversal of hepatoma cells resistance to anticancer drugs is correlated to cell proliferation kinetics, telomere length and telomerase activity

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3279-3285

  Chau, Nguyen Phong ^a   Deschatrette, Jean ^b   Wolfrom, Claire ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cisplatin; Drug resistance; Dynamics; Gene amplification; Hepatoma; Methotrexate; Telomerase; Telomeres

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; METHOTREXATE; TELOMERASE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HEPATOMA CELL; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; TELOMERE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; LIVER NEOPLASMS, EXPERIMENTAL; LOGISTIC MODELS; METHOTREXATE; PREDICTIVE VALUE OF TESTS; RATS; TELOMERASE; TELOMERE;

EID: 23344434272     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ciaiolo C, Ferrero D, Pugliese A, Biglino A, Marletto G, Tonello M, Colzani G and Marietti G: Enhancement of methotrexate cytotoxicity by modulation of proliferation activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line. Tumori 74: 537-542, 1988.
2. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Casadei-Giunchi D, Vio A, Saragoni A and Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43: 7-14, 1997.
3. Frei E 3rd, Richardson P, Avigan D, Bunnell C, Wheeler C and Elias A: The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Bone Marrow Transplant 9: 939-945, 1999.
4. Cara S and Tannock IF: Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 12: 23-27, 2001.
5. Haurie C, Dale DC and Mackey MC: Cyclical neutropenia and other periodic hematological disorders: a review of mechanisms and mathematical models. Blood 8: 2629-2640, 1998.
6. Supino R, Rodolfo M, Mariani M and Mapelli E: Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumori 78: 5-9, 1992.
7. Ferguson PJ and Cheng YC: Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res 49: 1148-1153, 1989.
8. Wolfrom C, Chau NP, Maigné J, Lambert JC, Ducot B, Guerroui S and Deschatrette J: Evidence for deterministic chaos in aperiodic oscillations of proliferative activity in long-term cultured Fao hepatoma cells. J Cell Sci 113: 1069-1074, 2000.
9. Deschatrette J, Lauga J, Maigné J and Wolfrom C: Telomeres and telomerase activity are regulated as a complex system in cultured hepatoma cells. Complexus 1: 134-141, 2003.
10. Deschatrette J, Ng KH, Gouthière L, Maigné J, Guerroui S and Wolfrom C: Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells. Anti-Cancer Drugs 75: 671-678, 2004.
11. Deschatrette J, Moore EE, Dubois M, Cassio D and Weiss MC: Dedifferentiated variants of a rat hepatoma: reversion analysis. Cell 19: 1043-1051, 1980.
12. Maigné J, Ng KH, Meunier-Rotival M, Poupon MF and Deschatrette J: Correlation between reversion of a dedifferentiated rat hepatoma line and the recovery of tumorigenicity. Cancer Res 48: 3258-3264, 1988.
13. Siddik ZH: Cisplatin: mode of action and molecular basis of resistance. Oncogene 20: 7265-7279, 2003.
14. Schimke RT: Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57: 1912-1917, 1986.
15. Zhao R and Goldman ID: Resistance to antifolates. Oncogene 22: 7431-7457, 2003.
16. Brown PC, Tlsty TD and Schimke RT: Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea. Mol Cell Biol 3: 1097-1107, 1983.
17. Mariani BD and Schimke RT: Gene amplification in a single cell cycle in Chinese hamster ovary cells. J Biol Chem 259: 1901-1910, 1984.
18. Johnston RN, Feder J, Hill AB, Sherwood SW and Schimke RT: Transient inhibition of DNA synthesis results in increased dihydrofolate reductase synthesis and subsequent increased DNA content per cell. Mol Cell Biol 6: 3373-3381, 1986.
19. 29 Schuetz JD, Gorse KM, Goldman ID and Westin EH: Transient inhibition of DNA synthesis by 5- fluorodeoxyuridine leads to overexpression of dihydrofolatereductase with increased frequency of methotrexate resistance. J Biol Chem 263: 7708-7712, 1988.
20. Renault E and Deschatrette J: Inductive effect of copper deficiency on the reversion of dedifferentiated rat hepatoma cells and on gene amplification. J Cell Science 107: 3251-3258, 1994.
21. Moretti P and Shore D: Multiple interactions in Sir protein recruitment by Rap1p at silencers and telomeres in yeast. Mol Cell Biol 21: 8082-8094, 2001.
22. Baur JA, Zou Y, Shay JW and Wright WE: Telomere position effect in human cells. Science 292: 2075-2077, 2001.
23. Nautiyal S, DeRisi JL and Blackburn EH: The genome-wide expression response to telomerase deletion in Saccharomyces cerevisiae. Proc Natl Acad Sc USA 99: 9316-9321, 2002.
24. Smith LL, Coller HA and Roberts JM: Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nature Cell Biol 5: 474-479, 2003.
25. Xiang H, Wang J, Mao Y, Liu M, Reddy VN and Li DW-C: Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway. Oncogene 27: 3784-3791, 2002.
26. Wang J, Xie LY, Allan S, Beach D and Hannon GJ: Myc activates telomerase. Genes Dev 12: 1769-1774, 1998.
27. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J and Dalla-Favera R: Direct activation of TERT transcription by c-MYC. Nature Genet 27: 220-224, 1999.
28. Cooper J, Nimmo ER, Allshire RC and Cech TR: Regulation of telomere length and function by a Myb-domain protein in fission yeast. Nature 385: 744-747, 1997.
29. Biroccio A, Gabellini C, Amodei S, Benassi B, Del Bufalo D, Elli R, Antonelli A, D'Incalci M and Zupi G: Telomere dysfunction increases cisplatin and eiteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 63: 632-638, 2003.
30. Misawa M, Tauchi T, Sashidi G, Nakajima A, Abe K, Ohyashiki JH and Ohyashiki K: Inhibition of telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 27: 1087-1092, 2002.
31. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP and Cowell JK: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16: 2243-2248, 1998.
32. Cressey TR, Tilby MJ and Newell DR: Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Eur J Cancer 38: 586-593, 2002.
33. Kiyozuka Y, Yamamoto D, Yang J, Uemura Y, Senzaki H, Adachi S and Tsubura A: Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells. Anticancer Res 20: 203-212, 2000.